Historical review from 2026-11-12. Current price and availability are unconfirmed; check the original marketplace.

← Back to 2026-11-12 Deals
#18

Stacker: Peptide Tracker

Health & FitnessListed on TrustMRR· Nov 2
$15.0K
Asking Price
$443/mo
Monthly Revenue
$434/mo
Monthly Profit
2.9x
Profit Multiple
N/A
Business Age
✨

Why We Picked This

Stacker is a niche health-tracking app with exceptional 98% profit margins and a 2.88x annual profit multiple—metrics that would normally merit strong consideration. However, the $442/mo revenue is below the threshold for meaningful cash flow evaluation, and the absence of customer count, retention data, or growth trajectory makes it impossible to assess business durability or acquisition value. The extreme margin suggests minimal ongoing costs rather than a scalable, profitable operation; this warrants direct clarification with the seller before serious evaluation.

👍

Strengths

  • ✓Verified financials on TrustMRR platform—$442/mo revenue and $434/mo profit are transparently disclosed
  • ✓Exceptional 98% profit margin—operational efficiency or minimal cost structure
  • ✓Reasonable 2.88x annual profit multiple at current asking price of $15,000
  • ✓Native iOS app in health-tracking niche with clear user value proposition
🔎

Details to confirm

  • •Monthly revenue of $442 is below meaningful cash flow threshold; seller should confirm customer count, active users, and whether revenue is recurring or transactional
  • •No retention, churn, or customer lifetime value data disclosed—critical for recurring business evaluation
  • •Absence of growth trend or revenue history; buyer should request 6–12 months of monthly revenue to assess stability and direction
  • •Extreme 98% margin raises questions about cost structure and scalability; clarify whether this reflects genuine efficiency, minimal operational load, or incomplete overhead allocation

Additional details to confirm

Evidence 60/100
Business age unavailableUnusually high reported profit margin

Buy vs Build: BUILD

22
AI-native cash cost
$3.5K–$7.5K
Estimated time
6 weeks
Asking price
$15.0K

Stacker is a single-platform (iOS) health tracker with standard features: user authentication, dose logging, reminders, and simple progress tracking. These components can be built rapidly using SwiftUI templates, Firebase for backend, and third-party reminder/notification libraries. At $15,000 asking price for $434/mo profit and no demonstrated customer traction, user count, or retention metrics, the acquisition risk is substantial relative to the reproducible software scope. A solo founder with an AI coding subscription could build a competitive MVP in 6–8 weeks for $3,500–$7,500 in cash. The purchase does not include verified paying customers, organic distribution, or durable revenue history—only an app binary and source code. Build is the lower-risk path unless the seller can demonstrate a meaningful, retained customer base and documented monthly revenue stability over time.

Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.

📊

Financial Snapshot

$5K
Annual Revenue
$5K
Annual Profit
$0.4K
Monthly Revenue
35 mo
Est. Payback
Profit Margin98%
📋

Business Overview

Helps users build personalized peptide stacks, log doses, get reminders, and track protocol progress and results in one iPhone app.

📌

Quick Facts

🏢
Type
Health & Fitness
🏪
Source
TrustMRR
📌
Listed
Nov 2, 2026

Deal Score

48
Below Average
Evidence confidence60/100
2.9x
Good Multiple
Asking$15.0K
MRR$443/mo
Profit$434/mo
Profit Multiple2.9x
View on TrustMRR →

Opens the original listing on TrustMRR

Share this review

Know a buyer or the founder? Send them the full analysis.

Share on X
New listings by email

See tomorrow’s businesses for sale.

Get new listings with asking prices, monthly profit, deal scores, and key risks.

The best reviewed deals, concise and evidence-first. Unsubscribe anytime.

Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.